Shaker Dakhil

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update.

Thomas M. Habermann, Edie Weller, V. A. Morrison et al. · Blood · 2004 · 52 citations

Medicine, Hematology, Oncology +11

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Nicholas C. Turner, Cristina Saura, Philippe Aftimos et al. · Journal of Clinical Oncology · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17